{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T04:00:58Z","timestamp":1741579258545,"version":"3.38.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,8]]},"DOI":"10.7759\/cureus.80274","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T05:05:19Z","timestamp":1741496719000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of TAFRO (Thrombocytopenia, Anasarca, Fever, Renal Insufficiency, and Organomegaly) Syndrome With Triple Combination Therapy of Corticosteroid, Tocilizumab, and Cyclosporine: A Case Report"],"prefix":"10.7759","author":[{"given":"Junki","family":"Morino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ookawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki Y","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, et al.. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016, 103:686-92. 10.1007\/s12185-016-1979-1","journal-title":"Int J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S127822","article-title":"TAFRO syndrome: current perspectives","volume":"9","author":"Sakashita K","year":"2018","unstructured":"Sakashita K, Murata K, Takamori M. TAFRO syndrome: current perspectives. J Blood Med. 2018, 9:15-23. 10.2147\/JBM.S127822","journal-title":"J Blood Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345060-00007","article-title":"Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders","volume":"45","author":"Faulds D","year":"1993","unstructured":"Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993, 45:953-1040. 10.2165\/00003495-199345060-00007","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03008-3","article-title":"Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan","volume":"113","author":"Fujimoto S","year":"2021","unstructured":"Fujimoto S, Kawabata H, Sakai T, et al.. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021, 113:73-80. 10.1007\/s12185-020-03008-3","journal-title":"Int J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2969","article-title":"Bone marrow findings of idiopathic multicentric Castleman disease: a histopathologic analysis and systematic literature review","volume":"40","author":"Belyaeva E","year":"2022","unstructured":"Belyaeva E, Rubenstein A, Pierson SK, Dalldorf D, Frank D, Lim MS, Fajgenbaum DC. Bone marrow findings of idiopathic multicentric Castleman disease: a histopathologic analysis and systematic literature review. Hematol Oncol. 2022, 40:191-201. 10.1002\/hon.2969","journal-title":"Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020, 135:1353-64. 10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.53.95","article-title":"Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report","volume":"53","author":"Inoue M","year":"2013","unstructured":"Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop. 2013, 53:95-9. 10.3960\/jslrt.53.95","journal-title":"J Clin Exp Hematop"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum DC","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, et al.. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017, 129:1646-57. 10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki N","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, et al.. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016, 91:220-6. 10.1002\/ajh.24242","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1834094","article-title":"Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease","volume":"62","author":"Ebisawa K","year":"2021","unstructured":"Ebisawa K, Shimura A, Honda A, Masamoto Y, Nakahara F, Kurokawa M. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. Leuk Lymphoma. 2021, 62:614-9. 10.1080\/10428194.2020.1834094","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto N","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, et al.. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005, 106:2627-32. 10.1182\/blood-2004-12-4602","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2004.00803.x","article-title":"Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes","volume":"9","author":"Tsujimura S","year":"2004","unstructured":"Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, Tanaka Y. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004, 9:1265-73. 10.1111\/j.1365-2443.2004.00803.x","journal-title":"Genes Cells"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-018-0319-0","article-title":"TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report","volume":"7","author":"Noda-Narita S","year":"2018","unstructured":"Noda-Narita S, Sumida K, Sekine A, et al.. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018, 7:162-8. 10.1007\/s13730-018-0319-0","journal-title":"CEN Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335925-successful-treatment-of-tafro-thrombocytopenia-anasarca-fever-renal-insufficiency-and-organomegaly-syndrome-with-triple-combination-therapy-of-corticosteroid-tocilizumab-and-cyclosporine-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T05:05:21Z","timestamp":1741496721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335925-successful-treatment-of-tafro-thrombocytopenia-anasarca-fever-renal-insufficiency-and-organomegaly-syndrome-with-triple-combination-therapy-of-corticosteroid-tocilizumab-and-cyclosporine-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.80274","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,8]]}}}